Form 483

New York Blood Center Enterprises Form 483, 2013-05-07

FDA issued a Form 483 to New York Blood Center Enterprises on 2013-05-07 with 5 public-safe observations.

483· Form 483 issuedBiologics5 observations

New York Blood Center Enterprises · Rye, United States · Issued May 7, 2013

Overview

  • 5 public-safe observations are available for this inspection.
  • 5 structured CFR citations are represented.
  • 1 investigator is tied to this Form 483.

Inspectional observations

Each observation cites the regulation FDA found the firm out of compliance with.

7 May 2013
21 CFR 211.100(b)

SOPs not followed / documented

Cited by Evelyn Taha

7 May 2013
21 CFR 211.198(b)(2)

Complaint Investigation/Follow-Up Findings

Cited by Evelyn Taha

7 May 2013
21 CFR 606.100(b)(15)

Schedules and procedures for equipment & calibration

Cited by Evelyn Taha

7 May 2013
21 CFR 606.160(a)(1)

Legibility and indelibility

Cited by Evelyn Taha

7 May 2013
21 CFR 803.17

Lack of Written MDR Procedures

Cited by Evelyn Taha

Inspected site

Inspection team

Cited regulations

CFR citations associated with this Form 483.

CitationWhat it coversCited
21 CFR 211.100(b)Cited across public-safe Form 483 observations1x
21 CFR 211.198(b)(2)Cited across public-safe Form 483 observations1x
21 CFR 606.100(b)(15)Cited across public-safe Form 483 observations1x
21 CFR 606.160(a)(1)Cited across public-safe Form 483 observations1x
21 CFR 803.17Cited across public-safe Form 483 observations1x

Source document

PDF
PDF available

Form 483 source document

The source document is available to authorized Atlas users.

Full 483 report

Get the verbatim text of all 5 observations

The source PDF and every observation in full, so your team sees exactly what was cited and how it was answered.

  • The site's full inspection history around this Form 483
  • Whether these citations escalated to a warning letter
  • The investigators involved and the citations they repeat elsewhere